Risk of Higher Research and Development Expenses in the Functional Materials Development Business
First written in FY2018. 14 of 15 entries say "Restated". Latest entry: FY2024-Q2.
The whole theme swung hardest in 2019: 4 of 13 companies on the "Worse" side.
7 other companies' latest entry also says "Restated".
- FY2024-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
It is stated that there have been no material changes in the risk of increased R&D expenses in the functional materials development business. - FY2024-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
It is stated that there have been no material changes in the risk of increased R&D expenses in the functional materials development business. - FY2023RestatedAnnual report
「R&D investment is made within a range consistent with the performance plans of the Group as a whole. However, if R&D expenses increase, the performance of the business may be adversely affected.」
The risk of increased R&D expenses associated with the development of functional materials and pharmaceuticals continues to be disclosed. - FY2023-Q3RestatedAnnual report
「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
It is stated that there have been no material changes in the risk of increased R&D expenses in the functional materials development business. - FY2023-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
It is stated that there have been no material changes in the risk of increased R&D expenses in the functional materials development business. - FY2022-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
It is stated that there have been no material changes in the risk of increased R&D expenses in the functional materials development business. - FY2021-Q3RestatedAnnual report
「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
It is stated that there have been no material changes in the risk of increased R&D expenses in the functional materials development business. - FY2021-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
It is stated that there have been no material changes in the risk of increased R&D expenses in the functional materials development business. - FY2020RestatedAnnual report
「R&D investment is made within a range consistent with the performance plans of the Group as a whole. However, if R&D expenses increase, the performance of the business may be adversely affected.」
The risk of increased R&D expenses associated with the development of functional materials and pharmaceuticals continues to be disclosed. - FY2020-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
It is stated that there have been no material changes in the risk of increased R&D expenses in the functional materials development business. - FY2020-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
It is stated that there have been no material changes in the risk of increased R&D expenses in the functional materials development business. - FY2019-Q3RestatedAnnual report
「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
It is stated in a consolidated entry that there have been no material changes in the risk of increased R&D expenses in the functional materials development business. - FY2019-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
It is stated in a consolidated entry that there have been no material changes in the risk of increased R&D expenses in the functional materials development business. - FY2019-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
It is stated in a consolidated entry that there have been no material changes in the risk of increased R&D expenses in the functional materials development business. - FY2018First statedAnnual report
「R&D investment is made within a range consistent with the performance plans of the Group as a whole. However, if R&D expenses increase, the performance of the business may be adversely affected.」
The risk of increased R&D expenses associated with the development of functional materials such as lactoferrin and pharmaceuticals such as ascochlorin derivatives is disclosed separately.